<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05076422</url>
  </required_header>
  <id_info>
    <org_study_id>1466-0001</org_study_id>
    <secondary_id>2020-002600-38</secondary_id>
    <nct_id>NCT05076422</nct_id>
  </id_info>
  <brief_title>A Study to Test How Well Overweight Men Tolerate Different Doses of BI 3006337</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Subcutaneous Doses of BI 3006337 in Overweight Healthy Male Subjects (Single-blind, Partially Randomised Within Dose Groups, Placebo-controlled, Parallel (Sequential) Group Design)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objectives of this trial are to investigate safety, tolerability and&#xD;
      pharmacokinetics of BI 3006337 in overweight, healthy male subjects following subcutaneous&#xD;
      administration of single-rising doses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2021</start_date>
  <completion_date type="Anticipated">June 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 18, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with drug-related adverse events (AEs)</measure>
    <time_frame>Up to 40 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in serum over the time interval from 0 extrapolated to infinity (AUC0-∞)</measure>
    <time_frame>Up to 40 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum measured concentration of the analyte in serum (Cmax)</measure>
    <time_frame>Up to 40 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to the maximum measured concentration of the analyte in serum (tmax)</measure>
    <time_frame>Up to 40 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 3006337 treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 3006337</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 3006337</intervention_name>
    <description>BI 3006337</description>
    <arm_group_label>BI 3006337 treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects according to the assessment of the investigator, as based on a&#xD;
             complete medical history including a physical examination, vital signs (Temperature,&#xD;
             blood pressure (BP), pulse rate (PR)), 12-lead ECG, and clinical laboratory tests&#xD;
&#xD;
          -  Age of ≥18 to ≤55 years at screening (SCR)&#xD;
&#xD;
          -  BMI of ≥25.0 to &lt;32.0 kg/m2 at SCR&#xD;
&#xD;
          -  A minimum absolute body weight (BW) of 75 kilograms (kg) at SCR&#xD;
&#xD;
          -  Male subjects who meet any of the following criteria from the administration of trial&#xD;
             medication until 30 days after administration of trial medication:&#xD;
&#xD;
               -  Use of adequate contraception, e.g. any of the following methods (of female&#xD;
                  partners) plus condom or sexually abstinence (if lifestyle-related): implants,&#xD;
                  injectables, vaginal contraceptives, intrauterine device, oral contraception&#xD;
                  (failure rate &lt;1%). In case of use of oral contraception women should have been&#xD;
                  stable on the same pill for a minimum of 3 months before taking study treatment.&#xD;
&#xD;
               -  Surgically sterilised/vasectomised (including hysterectomy with or without&#xD;
                  bilateral salpingectomy or bilateral oophorectomy of female partner. In case of&#xD;
                  salpingectomy or oophorectomy alone, only when the reproductive status of the&#xD;
                  woman has been confirmed by follow up hormone level assessment).&#xD;
&#xD;
               -  Postmenopausal female partner, defined as at least 1 year of spontaneous&#xD;
                  amenorrhea.&#xD;
&#xD;
          -  Signed and dated written informed consent prior to admission to the study, in&#xD;
             accordance with Good Clinical Practice (GCP) and local legislation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female gender&#xD;
&#xD;
          -  Any finding in the medical examination (including BP, PR or ECG) deviating from normal&#xD;
             and assessed as clinically relevant by the investigator&#xD;
&#xD;
          -  3 times repeated measurement of systolic BP outside the range of 90 to 150 mmHg,&#xD;
             diastolic BP outside the range of 50 to 90 mmHg, or PR outside the range of 40 to 100&#xD;
             bpm&#xD;
&#xD;
          -  Any laboratory value outside the reference range that the investigator considers to be&#xD;
             of clinical relevance, in particular, hepatic parameters Alanine Transaminase (ALT)&#xD;
             (1.25xupper limit of normal (ULN)), Aspartate Transaminase (AST) (1.25xULN) and Total&#xD;
             Bilirubin (T-BIL) (1.5xULN) or renal parameters (creatinine 1.25xULN) exceeding the&#xD;
             Upper Limit of Normal (ULN) as specified: after 2 times repeated measurements&#xD;
&#xD;
          -  Any evidence of a concomitant disease assessed as clinically relevant by the&#xD;
             investigator&#xD;
&#xD;
          -  Clinically relevant gastrointestinal, hepatic, renal, respiratory, cardiovascular,&#xD;
             metabolic, immunological or hormonal disorders&#xD;
&#xD;
          -  Diseases of the central nervous system (including but not limited to any kind of&#xD;
             seizures or stroke), and other relevant neurological or psychiatric disorders&#xD;
&#xD;
          -  History of relevant orthostatic hypotension, fainting spells, or blackouts&#xD;
&#xD;
          -  Chronic or relevant acute infections, including positive tests for Hepatitis (Hep) B&#xD;
             antigen/ Hep C antibodies, Human immunodeficiency virus (HIV)-1/2 antibodies and&#xD;
             Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)&#xD;
&#xD;
          -  Further exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SGS Life Science Services - Clinical Research</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Van Gucht</last_name>
      <phone>+32 471773447</phone>
      <email>Jonathan.vangucht@sgs.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).&#xD;
For more details refer to: http://trials.boehringer-ingelheim.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

